# Efficacy of budesonide suspension in the treatment of lobar pneumonia by fiberoptic bronchoscopic alveolar lavage

## TL;DR

This study shows that adding budesonide suspension to bronchoscopic alveolar lavage improves treatment outcomes for children with lobar pneumonia.

## Contribution

The study demonstrates that budesonide suspension enhances therapeutic efficacy and lung function in children with lobar pneumonia.

## Key findings

- The observation group had a higher total effective rate (90.91%) compared to the control group (81.82%).
- Budesonide improved immune function and reduced inflammatory markers like IL-6, CRP, and ESR.
- The treatment group showed faster symptom improvement and better lung function indicators.

## Abstract

To probe the efficacy of budesonide suspension in treating lobar pneumonia by fiberoptic bronchoscopic alveolar lavage.

A total of 176 preschool and school-age children with lobar pneumonia in the pediatric respiratory department of Binzhou Medical University Hospital from December 2020 to December 2021 were selected and divided into observation group (OG, n = 88) and control group (CG, n = 88) based on the wishes of their families. Children in both groups were given azithromycin sequential treatment. The CG was given fiberoptic bronchoscope alveolar lavage with sodium chloride injection, and the OG was treated with fiberoptic bronchoscope alveolar lavage with sodium chloride injection + inhalation of budesonide suspension. The treatment, inflammatory factor levels, immune function, lung function indicators, adverse reactions and clinical efficacy were compared between both groups.

The total effective rate of the OG was 90.91%, which was better than 81.82% of the CG (χ2 = 3.095, p < 0.05). After treatment, the serum IL-6, CRP and ESR levels declined, and IL-2 level was elevated in the OG relative to the CG (p < 0.05). The levels of IgM, IgA, IgG, FVC, FEV1, PEF, FEF25, FEF50, FEF75 and FEF25-75 in the OG were enhanced compared to the CG (p < 0.05). The antipyrexia time, the disappearance time of lung shadow, the improvement time of cough and expectoration, and the disappearance time of lung rales in the OG were shorter compared to the CG (p < 0.05).

Budesonide combined with fiberoptic bronchoscopy lavage in treating lobar pneumonia in children with Mycoplasma pneumoniae is effective in enhancing the therapeutic effect, relieving the clinical symptoms and signs of children faster, significantly reducing the inflammatory response, and significantly improving lung function. It is safe, effective and has no adverse reactions.